{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:37Z","timestamp":1787017117646,"version":"build-2736575974"},"reference-count":95,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This work was supported by the Division of Oncology, WashU School of Medicine, the Bonnie and Kerry Preete Foundation, and the John S. Conboy Prostate Cancer Research Fund.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,10,26]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Clinical trials of immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) have largely been unsuccessful despite promising preclinical studies and proven efficacy in other solid tumors. These disappointing clinical outcomes have been attributed to an immunosuppressive tumor microenvironment, a relative lack of infiltrating immune effector cells, and tumor-related and host-related factors, which collectively render prostate cancer a relatively immunologically \u201ccold\u201d tumor. Sipuleucel-T (Provenge), an autologous cellular immunotherapy, induces an immune response targeted against prostatic acid phosphatase. It received approval from the US Food and Drug Administration in 2010, marking the first immunotherapy to show an overall survival benefit in patients with mCRPC in large phase III randomized trials. Unfortunately, subsequent immunotherapy-based strategies have been less efficacious in mCRPC relative to other tumor types. Given the use of sipuleucel-T as a standard of care backbone, there is emerging interest in combining it with other immunotherapies, hormonal therapies, or chemotherapies to improve its clinical efficacy. This review summarizes past experiences and current knowledge of combining sipuleucel-T with other treatments and explores future approaches to enhance such combinatorial strategies.<\/jats:p>","DOI":"10.1136\/jitc-2025-012690","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T09:50:32Z","timestamp":1764928232000},"page":"e012690","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct00779402","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01338012","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00065442","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01487863","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01981122","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01431391","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01487863","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01981122","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00715104","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00715078","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01832870","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01804465","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03024216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01881867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01706458","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01818986","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02463799","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01833208","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06100705","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05751941","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03532217","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05751941","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05751941","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kavita","family":"Rawat","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varnika","family":"Punia","sequence":"additional","affiliation":[{"name":"Government Medical College and Hospital, Chandigarh, Punjab and Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker","family":"Mathews","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"McCoy","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbur","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad A","family":"Saeed","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-7631","authenticated-orcid":false,"given":"Russell K","family":"Pachynski","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"},{"name":"Siteman Cancer Center, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2026010701250974000_13.12.e012690.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026010701250974000_13.12.e012690.2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","article-title":"Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States","volume":"4","author":"Kelly","year":"2018","journal-title":"Eur Urol Focus"},{"key":"2026010701250974000_13.12.e012690.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2026010701250974000_13.12.e012690.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2026010701250974000_13.12.e012690.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2026010701250974000_13.12.e012690.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.038"},{"key":"2026010701250974000_13.12.e012690.7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Oncol"},{"key":"2026010701250974000_13.12.e012690.8","doi-asserted-by":"publisher","DOI":"10.1634\/THEONCOLOGIST.2020-0697"},{"key":"2026010701250974000_13.12.e012690.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"2026010701250974000_13.12.e012690.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.021"},{"key":"2026010701250974000_13.12.e012690.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962"},{"key":"2026010701250974000_13.12.e012690.12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050"},{"key":"2026010701250974000_13.12.e012690.13","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1002\/cam4.2375","article-title":"Pembrolizumab in men with heavily treated metastatic castrate\u2010resistant prostate cancer","volume":"8","author":"Tucker","year":"2019","journal-title":"Cancer Med"},{"key":"2026010701250974000_13.12.e012690.14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41391-024-00799-y","article-title":"A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and\/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis","volume":"28","author":"Mosalem","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026010701250974000_13.12.e012690.15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D"},{"key":"2026010701250974000_13.12.e012690.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114525"},{"key":"2026010701250974000_13.12.e012690.17","first-page":"2175","article-title":"Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer","volume":"6","author":"Burch","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2026010701250974000_13.12.e012690.18","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20040"},{"key":"2026010701250974000_13.12.e012690.19","first-page":"76","article-title":"Technology evaluation: APC-8015, Dendreon","volume":"4","author":"Rini","year":"2002","journal-title":"Curr Opin Mol Ther"},{"key":"2026010701250974000_13.12.e012690.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0638"},{"key":"2026010701250974000_13.12.e012690.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1317-2"},{"key":"2026010701250974000_13.12.e012690.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0079"},{"key":"2026010701250974000_13.12.e012690.23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4049\/jimmunol.159.1.472","article-title":"Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy","volume":"159","author":"Liu","year":"1997","journal-title":"J Immunol"},{"key":"2026010701250974000_13.12.e012690.24","article-title":"Dendritic cell-based immunotherapy for prostate cancer","volume":"2010","author":"J\u00e4hnisch","year":"2010","journal-title":"Clin Dev Immunol"},{"key":"2026010701250974000_13.12.e012690.25","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1200\/JCO.2000.18.23.3894","article-title":"Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells","volume":"18","author":"Small","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026010701250974000_13.12.e012690.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5252"},{"key":"2026010701250974000_13.12.e012690.27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24429"},{"key":"2026010701250974000_13.12.e012690.28","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM10-5608"},{"key":"2026010701250974000_13.12.e012690.29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jnci\/djaa021","article-title":"Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T","volume":"112","author":"Madan","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2026010701250974000_13.12.e012690.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0474-9"},{"key":"2026010701250974000_13.12.e012690.31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2020.38.6_suppl.321","article-title":"A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)","volume":"38","author":"Ross","year":"2020","journal-title":"JCO"},{"key":"2026010701250974000_13.12.e012690.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3126"},{"key":"2026010701250974000_13.12.e012690.33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2017.35.6_suppl.196","article-title":"Boosting long-term immune responses to sipuleucel-T (sip-T) by retreatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Beer","year":"2017","journal-title":"JCO"},{"key":"2026010701250974000_13.12.e012690.34","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1078-0432.CCR-22-3832","article-title":"Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials","volume":"29","author":"Antonarakis","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026010701250974000_13.12.e012690.35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/jnci\/djab025","article-title":"Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens","volume":"114","author":"Kibel","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2026010701250974000_13.12.e012690.36","doi-asserted-by":"crossref","unstructured":"Inman B , Vu T , Yu EY , et al . PD14-07 REAL-TIME IMAGING DEMONSTRATING T-CELL MEDIATED DESTRUCTION OF PROSTATIC ACID PHOSPHATASE (PAP)-EXPRESSING CELLS IN PATIENTS (PTS) TREATED WITH SIPULEUCEL-T (SIP-T). Journal of Urology 2018;199. doi:10.1016\/j.juro.2018.02.793","DOI":"10.1016\/j.juro.2018.02.793"},{"key":"2026010701250974000_13.12.e012690.37","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju268","article-title":"Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer","volume":"106","author":"Fong","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2026010701250974000_13.12.e012690.38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1486953","article-title":"Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer","volume":"8","author":"Hagihara","year":"2019","journal-title":"Oncoimmunology"},{"key":"2026010701250974000_13.12.e012690.39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3173"},{"key":"2026010701250974000_13.12.e012690.40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/2051-1426-3-S2-P145","article-title":"Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)","volume":"3","author":"Drake","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2026010701250974000_13.12.e012690.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1780"},{"key":"2026010701250974000_13.12.e012690.42","doi-asserted-by":"crossref","unstructured":"Gulley JL , Madan RA , Heery CR . Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. Am Soc Clin Oncol Educ Book 2013. doi:10.1200\/EdBook_AM.2013.33.e166","DOI":"10.14694\/EdBook_AM.2013.33.e166"},{"key":"2026010701250974000_13.12.e012690.43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-23-0652","article-title":"High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance","volume":"12","author":"Saeed","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2026010701250974000_13.12.e012690.44","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw261","article-title":"Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026010701250974000_13.12.e012690.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2334"},{"key":"2026010701250974000_13.12.e012690.46","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2014.21"},{"key":"2026010701250974000_13.12.e012690.47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/jco.2016.34.2_suppl.165","article-title":"Sipuleucel-T (sip-T)\u2013induced proliferative CD8+ T-cell responses to immunizing and secondary antigens","volume":"34","author":"Antonarakis","year":"2016","journal-title":"JCO"},{"key":"2026010701250974000_13.12.e012690.48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0073"},{"key":"2026010701250974000_13.12.e012690.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43937-7","article-title":"Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide","volume":"13","author":"Zedan","year":"2023","journal-title":"Sci Rep"},{"key":"2026010701250974000_13.12.e012690.50","doi-asserted-by":"crossref","unstructured":"Zorko NA , Makovec A , Elliott A , et al . Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes. Prostate Cancer Prostatic Dis 2024. doi:10.1038\/s41391-025-01009-z","DOI":"10.1038\/s41391-024-00797-0"},{"key":"2026010701250974000_13.12.e012690.51","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0145"},{"key":"2026010701250974000_13.12.e012690.52","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.annonc.2025.05.007","article-title":"Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study","volume":"36","author":"Graff","year":"2025","journal-title":"Ann Oncol"},{"key":"2026010701250974000_13.12.e012690.53","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2721","article-title":"1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study","volume":"34","author":"Graff","year":"2023","journal-title":"Ann Oncol"},{"key":"2026010701250974000_13.12.e012690.54","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-24-1595","article-title":"Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects","volume":"30","author":"Isaacsson Velho","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026010701250974000_13.12.e012690.55","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1200\/JCO.2017.35.15_suppl.3066","article-title":"A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"35","author":"Jha","year":"2017","journal-title":"JCO"},{"key":"2026010701250974000_13.12.e012690.56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002254","article-title":"Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"Sinha","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026010701250974000_13.12.e012690.57","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.015"},{"key":"2026010701250974000_13.12.e012690.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2026010701250974000_13.12.e012690.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2026010701250974000_13.12.e012690.60","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"2026010701250974000_13.12.e012690.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2026010701250974000_13.12.e012690.62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann Oncol"},{"key":"2026010701250974000_13.12.e012690.63","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026010701250974000_13.12.e012690.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"2026010701250974000_13.12.e012690.65","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"2026010701250974000_13.12.e012690.66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S122497","article-title":"Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer","volume":"6","author":"Scholz","year":"2017","journal-title":"Immunotargets Ther"},{"key":"2026010701250974000_13.12.e012690.67","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.2018.36.6_suppl.368","article-title":"Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC)","volume":"36","author":"Ku","year":"2018","journal-title":"JCO"},{"key":"2026010701250974000_13.12.e012690.68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002931","article-title":"Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T","volume":"9","author":"Dorff","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026010701250974000_13.12.e012690.69","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0019"},{"key":"2026010701250974000_13.12.e012690.70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002903","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026010701250974000_13.12.e012690.71","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.105929","article-title":"Step-dose IL-7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes","volume":"26","author":"Pandit","year":"2023","journal-title":"iScience"},{"key":"2026010701250974000_13.12.e012690.72","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02947-y"},{"key":"2026010701250974000_13.12.e012690.73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3392"},{"key":"2026010701250974000_13.12.e012690.74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003965"},{"key":"2026010701250974000_13.12.e012690.75","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14601","article-title":"IL-15 sustains IL-7R-independent ILC2 and ILC3 development","volume":"8","author":"Robinette","year":"2017","journal-title":"Nat Commun"},{"key":"2026010701250974000_13.12.e012690.76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.3329"},{"key":"2026010701250974000_13.12.e012690.77","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7470"},{"key":"2026010701250974000_13.12.e012690.78","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0009"},{"key":"2026010701250974000_13.12.e012690.79","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps5111","article-title":"A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"32","author":"Jha","year":"2014","journal-title":"JCO"},{"key":"2026010701250974000_13.12.e012690.80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9968"},{"key":"2026010701250974000_13.12.e012690.81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0169"},{"key":"2026010701250974000_13.12.e012690.82","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0241-8"},{"key":"2026010701250974000_13.12.e012690.83","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0333-y","article-title":"Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine","volume":"6","author":"Wargowski","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026010701250974000_13.12.e012690.84","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061419","article-title":"Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer","volume":"10","author":"Hannan","year":"2022","journal-title":"Biomedicines"},{"key":"2026010701250974000_13.12.e012690.85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4476"},{"key":"2026010701250974000_13.12.e012690.86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e16538","article-title":"Interim analysis of a pilot study: Impact of high-dose, single fraction radiation on immunogenicity of sipuleucel-T in metastatic castration resistant prostate cancer patients","volume":"37","author":"Yang","year":"2019","journal-title":"JCO"},{"key":"2026010701250974000_13.12.e012690.87","unstructured":"ClinicalTrials.gov . A single arm open-label, phase II study of sipuleucel-t with bipolar androgen therapy in men with metastatic castration-resistant prostate cancer. 2024."},{"key":"2026010701250974000_13.12.e012690.88","unstructured":"ClinicalTrials.gov . A phase II randomized study of sipuleucel-T with or without continuing new hormonal agents (NHA) in metastatic prostate cancer with PSA progression while on NHA and LHRH analog; Clinical Trial-NCT05751941 . 2024. Available: https:\/\/clinicaltrialsgov\/study\/NCT05751941?cond=NCT05751941&rank=1"},{"key":"2026010701250974000_13.12.e012690.89","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02085-6"},{"key":"2026010701250974000_13.12.e012690.90","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1200\/JCO.2022.40.16_suppl.5068","article-title":"A pilot trial of neoantigen DNA vaccine in combination with nivolumab\/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"40","author":"Shah","year":"2022","journal-title":"JCO"},{"key":"2026010701250974000_13.12.e012690.91","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21956"},{"key":"2026010701250974000_13.12.e012690.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.06.010"},{"key":"2026010701250974000_13.12.e012690.93","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41391-022-00493-x","article-title":"Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry","volume":"25","author":"Wei","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026010701250974000_13.12.e012690.94","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"key":"2026010701250974000_13.12.e012690.95","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0213-7"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:25:27Z","timestamp":1767777927000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":95,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/jitc-2025-012690"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012690","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}